Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes.
- Author:
Hui-Xin WAN
1
;
Jing-Kang SHEN
Author Information
1. Central Research Institute, Shanghai Pharmaceutical Holding Co., Ltd., Shanghai 201203, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Benzhydryl Compounds;
chemical synthesis;
chemistry;
pharmacology;
Diabetes Mellitus, Type 2;
drug therapy;
Glucosides;
chemical synthesis;
chemistry;
pharmacology;
Humans;
Hypoglycemic Agents;
chemical synthesis;
chemistry;
pharmacology;
Molecular Structure;
Monosaccharides;
chemical synthesis;
chemistry;
pharmacology;
Sodium-Glucose Transporter 1;
metabolism;
Sodium-Glucose Transporter 2;
antagonists & inhibitors;
metabolism;
Structure-Activity Relationship
- From:
Acta Pharmaceutica Sinica
2012;47(6):716-724
- CountryChina
- Language:Chinese
-
Abstract:
Sodium-glucose co-transporters are a family of glucose transporter found in the intestinal mucosa of the small intestine (SGLT-2) and the proximal tubule of the nephron (SGLT-1 and SGLT-2). They contribute to renal glucose reabsorption and most of renal glucose (about 90%) is reabsorbed by SGLT-2 located in the proximal renal tubule. Selectively inhibiting activity of SGLT-2 is an innovative therapeutic strategy for treatment of type 2 diabetes by enhancing urinary glucose excretion from the body. Therefore SGLT-2 inhibitors are considered to be potential antidiabetic drugs with an unique mechanism. This review will highlight some recent advances and structure-activity relationships in the discovery and development of SGLT-2 inhibitors including O-glycoside, C-glycoside, C, O-spiro glycoside and non glycosides.
